LEO Pharma
Privately held: no public share price
Assets
(6 total)
6Total Assets
5Approved
0Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
brodalumab(Siliq) | Approved | IL-17 receptor AMonoclonal antibody | Psoriasis |
| Approved | Vitamin D receptor + Glucocorticoid receptorSmall molecule | Psoriasis | |
| Approved | Vitamin D receptor + Glucocorticoid receptorSmall molecule | Psoriasis | |
spesolimab(Spevigo) | Approved | IL-36 receptorMonoclonal antibody | PsoriasisHidradenitis Suppurativa |
tralokinumab(Adbry) | Approved | IL-13Monoclonal antibody | Atopic Dermatitis |
| Phase 2 | IL-22 receptor subunit alpha-1 (IL-22RA1)Monoclonal antibody | Atopic Dermatitis |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
13 November 2026ApprovaldelgocitinibNMPA approves Anzupgo cream in chronic hand eczema
CN, NMPA · Source ↗
Financial reports
No financial reports recorded.